Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System
Matthew Sussman, Amy K. O’Sullivan, Ankit Shah, et al.
Journal of Managed Care & Specialty Pharmacy (2019) Vol. 25, Iss. 7, pp. 823-835
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
Roger S. McIntyre, Mohammad Alsuwaidan, Bernhard T. Baune, et al.
World Psychiatry (2023) Vol. 22, Iss. 3, pp. 394-412
Open Access | Times Cited: 243
Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials
Lisa Brown, Joseph D. Stanton, Kanika Bharthi, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 112, Iss. 6, pp. 1303-1317
Open Access | Times Cited: 71
Clinical research challenges posed by difficult-to-treat depression
A. John Rush, Harold A. Sackeïm, Charles R. Conway, et al.
Psychological Medicine (2022) Vol. 52, Iss. 3, pp. 419-432
Open Access | Times Cited: 59
Projecting the 10-year costs of care and mortality burden of depression until 2032: a Markov modelling study developed from real-world data
Vivien Kin Yi Chan, Man Yee Mallory Leung, Sandra S. M. Chan, et al.
The Lancet Regional Health - Western Pacific (2024) Vol. 45, pp. 101026-101026
Open Access | Times Cited: 8
Deep brain stimulation of the “medial forebrain bundle”: a strategy to modulate the reward system and manage treatment-resistant depression
Albert J. Fenoy, João Quevedo, Jair C. Soares
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 574-592
Closed Access | Times Cited: 43
Eficácia da cetamina e esketamina no tratamento da depressão: revisão das evidências e perspectivas futuras
RAPHAELA NOGUEIRA DUTRA, Mario Vitor Ferreira Nascimento, João Pedro Silva Gontijo, et al.
STUDIES IN HEALTH SCIENCES (2025) Vol. 6, Iss. 1, pp. e14206-e14206
Closed Access
Trajectories of pharmacological therapies for treatment-resistant depression: a longitudinal study
Julia DiBello, Xiaomo Xiong, Xinyue Liu, et al.
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access
Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization
Roger S. McIntyre, Brad Millson, G. Sarah Power
Journal of Affective Disorders (2020) Vol. 277, pp. 30-38
Open Access | Times Cited: 40
Economic impact of treatment-resistant depression: A retrospective observational study
Víctor Pérez, Miquel Roca, Jordi Alonso, et al.
Journal of Affective Disorders (2021) Vol. 295, pp. 578-586
Open Access | Times Cited: 37
Neuromodulation in Psychiatric disorders: Experimental and Clinical evidence for reward and motivation network Deep Brain Stimulation: Focus on the medial forebrain bundle
Máté D. Döbrössy, Chockalingam Ramanathan, Danesh Ashouri Vajari, et al.
European Journal of Neuroscience (2020) Vol. 53, Iss. 1, pp. 89-113
Open Access | Times Cited: 29
Real-world evidence from a European cohort study of patients with treatment resistant depression: Healthcare resource utilization
K. Heerlein, Serafino De Giorgi, G. Degraeve, et al.
Journal of Affective Disorders (2021) Vol. 298, pp. 442-450
Open Access | Times Cited: 25
Mortality-causing mechanisms and healthcare resource utilisation of treatment-resistant depression: A six-year population-based cohort study
Vivien Kin Yi Chan, Edmund Chi Lok Cheung, Sandra S. M. Chan, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 22, pp. 100426-100426
Open Access | Times Cited: 15
Deep Brain Stimulation of the Medial Forebrain Bundle for Treatment-Resistant Depression: A Systematic Review Focused on the Long-Term Antidepressive Effect
Luigi Gianmaria Remore, Meskerem Tolossa, Wexin Wei, et al.
Neuromodulation Technology at the Neural Interface (2023) Vol. 27, Iss. 4, pp. 690-700
Closed Access | Times Cited: 8
Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression
Katherine E. Kabotyanski, Ricardo A. Najera, Garrett P. Banks, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Sex differences in type of exercise associated with depression in South Korean adults
Hyunkyu Kim, Wonjeong Jeong, Junhyun Kwon, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 16
Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST): study protocol for a randomized non-inferiority trial of magnetic seizure therapy versus electroconvulsive therapy
Zafiris J. Daskalakis, Carol Tamminga, Alanah Throop, et al.
Trials (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 15
The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder
Alix Arnaud, Ellison Suthoff, Rita M. Tavares, et al.
PharmacoEconomics (2021) Vol. 39, Iss. 6, pp. 691-706
Open Access | Times Cited: 15
Role of Ketamine in the Treatment of Psychiatric Disorders
Sahar Derakhshanian, Maxine Zhou, Alexander Rath, et al.
Health psychology research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 15
Economic evaluation of interventions for treatment-resistant depression: A systematic review
Laura A. Hannah, Cathy M. Walsh, Louise Jopling, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 5
Could ketamine be the answer to treating treatment-resistant major depressive disorder?
Abdullah Ramadan, Islam Mansour
General Psychiatry (2020) Vol. 33, Iss. 5, pp. e100227-e100227
Open Access | Times Cited: 15
Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability
Michael D. Kritzer, Chi‐Un Pae, Prakash S. Masand
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 725-732
Open Access | Times Cited: 9
#TreatmentResistantDepression: A qualitative content analysis of Tweets about difficult‐to‐treat depression
Amelia Talbot, Tori Ford, Sara Ryan, et al.
Health Expectations (2023) Vol. 26, Iss. 5, pp. 1986-1996
Open Access | Times Cited: 4
Patient perspectives of lithium and quetiapine augmentation treatment in treatment-resistant depression: A qualitative assessment
Lucas McKeown, R. Taylor, Elana Day, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 5, pp. 557-565
Open Access | Times Cited: 7
Association between changes in handgrip strength and depression in Korean adults: a longitudinal panel study
Hyunkyu Kim, Wonjeong Jeong, Seung Hoon Kim, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Descriptive analysis of the economic burden of treatment resistance in a major depressive episode
Qian Cai, John J. Sheehan, Bingcao Wu, et al.
Current Medical Research and Opinion (2019) Vol. 36, Iss. 2, pp. 329-335
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top